N-13-Ammonia¹³N-ammonia

Quick Answer

N-13-ammonia is a cyclotron-produced cardiac PET perfusion tracer with high, flow-stable first-pass extraction, giving excellent image quality and accurate absolute myocardial blood flow / flow reserve. Its ~10-minute half-life permits some exercise protocols (unlike Rb-82) but requires an on-site or nearby cyclotron — logistics, not performance, limit its use.

Mechanism

Ammonia freely diffuses into myocytes and is metabolically trapped by conversion to glutamine via glutamine synthetase. Its high extraction holds better at elevated flows than Rb-82 or thallium, making it particularly accurate for hyperemic MBF quantification.

Production & Logistics

A cyclotron product with a ~10-minute half-life — needs proximate production but allows more flexible protocols than the ultra-short Rb-82, including limited exercise stress in suitable setups.

Clinical Indications

• Cardiac PET myocardial perfusion imaging and MBF/MFR quantification.
• Settings requiring the highest image quality and accurate flow at high hyperemic flows.
• Cases where a cyclotron is available and superior flow accuracy is desired.

Protocol Notes

• Typical activity ~10–20 mCi; dynamic (list-mode) acquisition for flow modeling; gated data for function.
• Vasodilator or (where feasible) exercise stress; hold caffeine for vasodilator studies.
• Allow inter-injection decay (short half-life) between rest and stress.

Interpretation Highlights

• Integrate relative perfusion, gated function, and absolute MBF/MFR.
• Higher, more flow-independent extraction gives reliable hyperemic flow values.
• Liver and lung uptake early after injection can interfere with inferior/lateral wall assessment — time imaging appropriately.

Reporting Checklist

• Report relative perfusion, gated LVEF/volumes/TID, and MBF/MFR (global/regional).
• Note early liver/lung activity if it affects inferolateral assessment.
• State stress type and caffeine-hold status.

Common Pitfalls

• Liver and lung uptake interfering with inferior/lateral wall assessment early after injection.
• Logistics (cyclotron proximity), not performance, limiting availability.
• Caffeine blunting hyperemia (vasodilator studies).

Board Pearls

N-13-ammonia is a cyclotron-produced cardiac PET perfusion tracer with high, more flow-independent first-pass extraction (metabolic trapping via glutamine synthetase) — excellent images and accurate absolute MBF/MFR, holding better than Rb-82 at high hyperemic flows.

Its ~10-minute half-life permits some exercise protocols (unlike Rb-82's 76 s) but requires an on-site/nearby cyclotron — logistics, not performance, limit its use.

Liver and lung uptake early after injection can obscure the inferior/lateral wall — a timing-dependent pitfall. The trade-off vs Rb-82 is the recurring cardiac-PET decision: N-13 offers superior flow accuracy at the cost of cyclotron dependence, whereas Rb-82's generator supply drives high-volume convenience.

Related Pages

• Protocol: Cardiac PET perfusion & MBF; contrast tracer: Rubidium-82.
• Related: Nuclear cardiology overview; pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A metabolic-trapping mechanism cartoon (diffusion → glutamine synthetase).
• An extraction-vs-flow comparison (N-13 vs Rb-82 vs Tl).
• A liver/lung interference timing schematic.

Self-Check